On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.

The surge was driven by Moderna and Merck jointly announcing that their pivotal Phase III clinical trial Interpath-001 achieved positive results. The trial evaluated intismeran autogene, a personalized neoantigen therapy, in combination with Keytruda for patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, with no new safety signals identified.

This marks the first Phase III trial success for mRNA technology in oncology, representing a major milestone for personalized immunotherapy. The two companies stated they plan to engage regulatory authorities regarding submission of the combination therapy. William Blair subsequently upgraded Moderna to Outperform. Merck shares rose over 7%, while sector peer BioNTech gained 18.9% on the broader mRNA platform validation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)